Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Phasellus varius turpis
Original price was: $87.00.$76.00Current price is: $76.00.Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
-
Quick View
Mauris elit magna, aliquet
$50.00Add to cartFusce sagittis tellus eget ante gravida euismod. Mauris interdum, neque eu hendrerit aliquet, diam nisi fringilla nisi, at convallis ante velit sed erat. Vestibulum mollis lorem ut molestie pharetra. Sed pretium quam lacinia, placerat urna a, tincidunt massa. Mauris elit magna, aliquet blandit mauris eu
-
Quick View
Pellentesque dignissim sapien semper
$78.00Add to cartCras luctus ultricies ex luctus malesuada. Fusce imperdiet interdum consectetur. Pellentesque dignissim sapien semper consequat sollicitudin. Phasellus iaculis libero ac placerat aliquam. Etiam a velit eu diam consequat vestibulum. Ut a malesuada nulla. Vivamus quis maximus nisi, vel molestie sapien. Nunc pharetra finibus elit sed consectetur.
-
Quick View
Fusce nec diam et dolor
$45.00Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
Reviews
There are no reviews yet.